Press Releases

Press Releases

Date Title and Summary Additional Formats
Apr 24, 2018 Catalyst Pharmaceuticals Introduces New Corporate Website

CORAL GABLES, Fla. , April 24, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today is

Apr 19, 2018 Catalyst Pharmaceuticals Announces Enrollment of First Patient in Phase 3 Trial of Firdapse® in MuSK Antibody Positive Myasthenia Gravis

Pivotal Study sites in U.S. and Italy CORAL GABLES, Fla. , April 19, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular

Mar 29, 2018 Catalyst Pharmaceuticals Announces Submission of New Drug Application for Firdapse® for Treatment of Lambert-Eaton Myasthenic Syndrome
CORAL GABLES, Fla. , March 29, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced its
Mar 14, 2018 Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update
--Firdapse ® NDA to be Resubmitted Before the End of this Quarter --Significant Progress with MuSK-MG Regulatory and Clinical Program -- $84M Year-End Cash and Investments --Company to Host Quarterly Conference Call at 5:00 pm ET Today CORAL GABLES, Fla.
Mar 12, 2018 Catalyst Pharmaceuticals Announces Date and Time Change for Fourth Quarter and Year-End Financial Results Call and Webcast
CORAL GABLES, Fla. , March 12, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that
Mar 08, 2018 Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End Financial Results Conference Call and Webcast on Thursday, March 15th, 2018
CORAL GABLES, Fla. , March 08, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that
Feb 28, 2018 Catalyst Pharmaceuticals Announces Its Continuing Support for Rare Disease Day 2018
CORAL GABLES, Fla. , Feb. 28, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the
Feb 12, 2018 Catalyst Pharmaceuticals Announces Plans to Resubmit New Drug Application for Firdapse®
Positive meeting with the FDA about the resubmission of an NDA for Firdapse Resubmission of NDA for Firdapse on schedule for end of the first quarter CORAL GABLES, Fla. , Feb. 12, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on
Feb 07, 2018 Catalyst Pharmaceuticals to Present at Two Upcoming Investor Conferences
CORAL GABLES, Fla. , Feb. 07, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today